• Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Before Header

  • Axis Clinicals USA

Axis Clinicals

Contract Research Organization

  • Home
  • About Us
    • Our DNA
    • Our Core Values
    • Your Preferred Partner of Choice – WHY?
    • Our Focus
    • Our Leadership
    • Accreditations
    • Global Locations
  • Services
    • BA | BE Studies
    • PK | PD and Patient Studies
    • Bio-Analytical Services
    • Phase I
    • Phase II-IV
    • Project Management
    • PK | Biostatistics & Programming
    • Medical Writing
    • Regulatory Services
    • Quality Assurance and Compliance
    • Clinical Data Management
    • Clinical Central Lab
  • Careers
  • News & Media
  • Contact Us
  • Investors
    • Annual Report
  • Home
  • About Us
    • Our DNA
    • Our Core Values
    • Your Preferred Partner of Choice – WHY?
    • Our Focus
    • Our Leadership
    • Accreditations
    • Global Locations
  • Services
    • BA | BE Studies
    • PK | PD and Patient Studies
    • Bio-Analytical Services
    • Phase I
    • Phase II-IV
    • Project Management
    • PK | Biostatistics & Programming
    • Medical Writing
    • Regulatory Services
    • Quality Assurance and Compliance
    • Clinical Data Management
    • Clinical Central Lab
  • Careers
  • News & Media
  • Contact Us
  • Investors
    • Annual Report

News & Media

You are here: Home / News & Media

Regulatory Inspections and Accreditations

AXIS Clinicals Limited conducted bioequivalence studies to support marketing authorization for various regulated markets including US FDA, Europe, TGA, ANVISA, WHO, DCGI, Health Canada, NPRA Malaysia, AEMPS Spain, INFARMED Portugal etc. for various sponsors. Our facility has been audited and approved by various global regulatory agencies and accreditation bodies and the details were described in the following table.

For a summary of regulatory inspections and approvals Click here


US-FDA: 2nd to 6th March 2020, AXIS completed 34th Audit by US FDA

UK-MHRA: Dates: 4th to 8th June 2018, AXIS completed 4th Audit by UK MHRA

WHO: Dates: 18th to 21st December 2017, AXIS completed 2nd Audit by WHO

GCC-DR (Gulf Central Committee for Drug Registration): Dates: 15th to 16th February 2016 , Approved

MCC (Medicines Control Council) – South Africa: Dates: 25th to 27th March 2017, Approved

NPRA (National Pharmaceutical Regulatory Agency) – Malaysia: Dates: 18th – 22nd June 2018 Approved

INFARMED (Portuguese National Authority of Medicines and Health Products): Dates: 18th – 20th June 2018 Approved

AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) – Spain: Dates: 17th – 21st Dec 2018 Approved


Events in 2020

CPhI China 2020
Shanghai, China
16th – 18th December 2020

CPhI Worldwide 2020
Fiera Milano, Rho, Italy
31st August – 02nd September 2021

Primary Sidebar

Menu

  • Home
  • About Us
    • Our DNA
    • Our Core Values
    • Your Preferred Partner of Choice – WHY?
    • Our Focus
    • Our Leadership
    • Accreditations
    • Global Locations
  • Services
    • BA | BE Studies
    • PK | PD and Patient Studies
    • Bio-Analytical Services
    • Phase I
    • Phase II-IV
    • Project Management
    • PK | Biostatistics & Programming
    • Medical Writing
    • Regulatory Services
    • Quality Assurance and Compliance
    • Clinical Data Management
    • Clinical Central Lab
  • Careers
  • News & Media
  • Contact Us
  • Investors
    • Annual Report

Footer

  • About Us
  • Our DNA
  • Our Core Values
  • Your Preferred Partner of Choice
  • Our Focus
  • Our Leadership
  • Accreditations
  • Global Locations
  • Services
  • BA | BE Studies
  • PK | PD and Patient Studies
  • Bio-Analytical Services
  • Phase II-IV
  • Project Management
  • PK | Biostatistics & Programming
  • Medical Writing
  • Regulatory Services
  • Quality Assurance and Compliance
  • Clinical Data Management
  • Clinical Central Lab
  • Careers
  • News & Media
  • Contact Us

Copyright © 2023 · Axis Clinicals